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1INTRODUCTION
Spinal anaesthesia is simple, easy to perform and has got a definite
endpoint for successful positioning of needle. The spinal analgesia is rapid
in onset and the spread of analgesic can be controlled. It requires a small
dose of local anaesthetic and yet produces profound sensory and motor
blockade.
After the introduction of local anaesthetics, diverse classes of drugs
like epinephrine, opioids, ketamine, neostigmine etc have been added as
adjuvants to local anaesthetics in an attempt to prolong analgesia and
reduce the incidence of side effects.
Pain is defined as an “unpleasant sensory and emotional experience
associated with actual or potential tissue damage or described in terms of
such damage”. Surgical trauma and pain is a real problem to the patient
during postoperative period.
After all the efforts taken to make the intra-operative period pain
free and stress free, the patients are left to fend for themselves in the post
operative period.
Post operative pain is unfortunately under treated. This is due to
traditional fear of respiratory depression and addiction and also lack of
knowledge of pharmacodynamics and pharmacokinetics of opioid
analgesics.
2As the anaesthesiologist alleviates the pain of the patient, he scores
as the ideal person to manage postoperative pain.
The use of local anaesthetics like bupivacaine has been unable to
provide analgesia for a longer duration. Most patients require further
analgesia during the post-operative period. Various adjuvants are added to
local anaesthetics for this. Among the list of  local anaesthetic adjuncts,
magnesium has many advantages.
Magnesium blocks N-methyl d-aspartate (NMDA) channels in a
voltage dependent fashion and this NMDA antagonism can prevent the
induction of central sensitisation due to peripheral nociceptive stimulation
[3].Magnesium has been called “Nature’s physiological calcium channel
Blocker”.
Buprenorphine is a partial agonist antagonist ,when added to
bupivacaine is known to increase the duration of analgesia at least by 12–
15 hours and it is not associated with any significant fall in BP or pulse
rate. It is a thebaine derivative (naturally occurring opium alkaloid) with
powerful agonist action at μ opioids receptors and partial antagonist action
and does not cause addiction or physical dependence. Intrathecal doses are
smaller and have prolonged and profound analgesia because of its highly
lipophilic nature.
Literature review showed a paucity of studies comparing the effects
of buprenorphine and magnesium sulphate given intrathecally along with
30.5% bupivacaine. Hence, the present study was undertaken to evaluate the
onset, duration of sensory and motor block quality and duration of
postoperative analgesia of magnesium sulphate and buprenorphine given
intrathecally with hyperbaric 0.5% bupivacaine in patients undergoing
infraumbilical surgeries.
4REVIEW OF LITERATURE
1. Wolff J et al (1986) in his study compared epidural buprenorphine
0.3 mg with 4 mg of epidural morphine for postoperative pain relief
in the first 24 hours after major orthopaedic surgery. Duration of
action was 620 minutes with buprenorphine with no side effects and
580 minutes with morphine with pruritis and urinary retention.
2. Capogna et al (1988), in their study compared intrathecal 0.03 mg
buprenorphine with bupivacaine 30 mg for post operative analgesia
in the elderly patient showed prolonged analgesia with minimal
disturbance of consciousness and comfortable breathing.
3. Sen M (1992) studied intrathecal buprenorphine for post operative
analgesia in orthopaedic surgery. Either hyperbaric bupivacaine 1 ml
in group A (30 cases) or bupivacaine 1 ml and buprenorphine 300
micrograms in combination was given, only minimal disturbance of
consciousness and respiration were observed.
4. Sunil dixit et al., studied to compare intrathecal bupivacaine (0.5%)
and buprenorphine (60 µg with bupivacaine (0.5%) for postoperative
analgesia in caesarean section. Sixty parturient undergoing elective
lower segment caesarean section were randomly selected after
dividing into two groups of 30 each. Control Group (C) received
1.70 ml (8.5mg) of bupivacaine (0.5%) while patients of study group
5(S) received 1.70 ml (8.5mg) bupivacaine 0.5%+(60µg)
buprenorphine. Onset of analgesia was 5.35±1.79 min in control
group, while 1.85±1.39 min in study group (P<0.001). The total
duration of analgesia was prolonged from 145.16±25.86 min in
Control group to 491.26± 153.97 min in Study group.
5. Egan Lanz et al (1984), in their double blind study of post –
operative analgesia, 158 patients who were given epidural analgesia
with mepivacaine or bupivacaine with buprenorphine for
orthopaedic surgery of lower extremities found that analgesia after
0.15 mg of Buprenorphine was superior to that after no injections for
6 hours after surgery. 0.3 mg of buprenorphine was superior both to
no injections and to 0.15 mg of buprenorphine until 12th hour
without any evidence of late respiratory depression. They concluded
that epidural administration of 0.3mg of Buprenorphine may be
recommended for post operative analgesia following orthopaedic
surgery of lower extremities.
6. Green DW et al (1985), in a randomized double blind trail
comparing morphine and buprenorphine and post operative
analgesia combined with droperidol was conducted in 60 patients.
Compared with morphine, taken as the standard analgesic,
buprenorphine was shown to be a satisfactory analgesic for major
surgery with no difference in incidence of unwanted effects.
67. Nishimi et al (1994) studied the effect of intrathecal administration
of opioid on minimum alveolar concentration and postoperative pain
relief a comparison of morphine and buprenorphine showed:•
Intrathecal administration of 0.05 mg and 0.075 mg of
buprenorphine has shown analgesic effect without any side effects.
With morphine 0.5 mg there was adequate post – operative analgesia
with severe pruritus.
8. Buvendran et al conducted a study evaluating whether intrathecal
magnesium could potentiate intrathecal opioid (fentanyl) analgesia
in patients requiring labour analgesia. Patients were allocated into 2
groups. Group F received 0.5 ml fentanyl (25 mcg) and 3 ml normal
saline whereas Group F+ M received 0.5 ml fentanyl (25 mcg) and 3
ml magnesium sulphate(50 mg) . The duration of spinal analgesia
was prolonged  in Group F+ M (75mins) compared with group F (60
mins). There were no differences in the demographic characteristics,
hemodynamic parameters and foetal heart rate.
9. Kroin et al demonstrated in his study that magnesium sulphate
potentiates morphine analgesia when administered intrathecally in
rats and suggested that intrathecal magnesium sulphate may be a
useful adjuvant to spinal morphine analgesia. Histological
evaluation of the spinal cord also showed identical histologic
changes with the control group and the animals had no neurological
7deficit. They demonstrated that intrathecal mgso4 has a safety
profile.
10. Okojie NQ et al (2012) conducted a study to determine the effect of
intrathecal magnesium sulphate to bupivacaine spinal anaesthesia for
transurethral resection of the prostate. Patients were randomized to
two groups. Group S received 3ml of 0.5% heavy bupivacaine in
addition to 1ml saline while Group M received 100mg of MgSO in
addition to 3ml of bupivacaine. Onset time of sensory and motor
block, time maximal block height was reached, duration of spinal
anaesthesia, pain scores and the total analgesics used in the
postoperative period were all recorded and analyzed. They
concluded that the addition of intrathecal magnesium sulphate to
bupivacaine spinal anaesthesia significantly prolonged the duration
of spinal anaesthesia and also reduced the postoperative analgesic
requirement without additional side effects.
11.Bharat aroara et al (2015) conducted a study to evaluate the onset,
duration of sensory and motor block, hemodynamic effects, duration
and quality of postoperative analgesia, and adverse effects of
magnesium or fentanyl given intrathecally with hyperbaric 0.5%
bupivacaine in patients with mild preeclampsia undergoing elective
caesarean sections. They concluded that the addition of magnesium
sulfate 50 mg to bupivacaine for sub-arachnoid block prolongs the
8duration of analgesia and reduces postoperative analgesic
requirements without additional side effects and adverse neonatal
outcomes.
12.Mamta kandelwal et al (2017) conducted a study to evaluate and
compare the analgesic efficacy of clonidine and magnesium when
used as an additive to intrathecal 0.5% hyperbaric bupivacaine in
lower abdominal surgeries. Ninety patients were randomly allocated
into three groups. Group B received 3 mL of 0.5% hyperbaric
bupivacaine with 1 mL of normal saline, Group C received 3 mL of
0.5% hyperbaric bupivacaine with 1 mL (30 µg) of clonidine and
Group M received 3 mL of 0.5% hyperbaric bupivacaine with 1 mL
(50 mg) magnesium sulphate. They concluded that intrathecal
clonidine added to bupivacaine prolongs the duration of post‑
operative analgesia, and hastens the onset and prolongs the duration
of sensory and motor block compared to magnesium or controls.
13. Kaushic A Theerth et al (2016) conducted  a study to compare the
effects of intrathecal magnesium sulphate with buprenorphine as
adjuvants to bupivacaine. 90 adult patients scheduled for below
umbilicus surgeries were randomized into three groups of 30 each.
They received 2.75ml of 0.5% hyperbaric bupivacaine mixed with
either 0.5ml of 10% magnesium sulphate(50mg) or 0.5ml of
buprenorphine(150μg) or 0.5ml of sterile water(placebo). Onset,
9duration of sensory and motor block and duration of total analgesia
were studied. The duration of spinal anaesthesia did not increase
with the addition of magnesium, but did so with buprenorphine.
However, it significantly prolonged the time for first analgesic
request though to a lesser extent than buprenorphine, thus
substantiating its use in postoperative analgesia.
14. Katiyar et al conducted a study to to evaluate the effects of additives
fentanyl and magnesium sulphate along with bupivacaine during
spinal anaesthesia for prolongation of analgesia and motor blockade.
A randomised study was conducted in 120 patients of either sex of
American Society of Anesthesiologists physical status I and II,
posted for infraumbilical surgeries. Patients were randomly allocated
to four groups and were given the following drugs intrathecally as
per group distribution; group A - bupivacaine 15 mg (0.5% heavy)
with fentanyl 25 μg, group B - bupivacaine 15 mg (0.5% heavy)
with magnesium 100 mg, group C - bupivacaine 15 mg (0.5%
heavy) with magnesium 50 mg and group D - bupivacaine 15 mg
(0.5% heavy) with 0.5 ml normal saline. Parameters monitored were
duration of analgesia along with haemodynamic parameters and side
effects. They concluded that addition of magnesium sulphate at 100
mg dose or fentanyl 25 μg as adjuvants to intrathecal bupivacaine
significantly prolongs the duration of analgesia, though in the given
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doses, magnesium provides better haemodynamic stability than
fentanyl, with fewer side effects.
15.Calleno D et al (1989) spinal buprenorphine for post operative
analgesia after ceasarian section. Group A (controls n = 15) received
hyperbaric bupivacaine; group B and C received the same but with
the addition of 0.03 mg or 0.045 mg buprenorphine, respectively.
Patient receiving higher dose had longer effect of 420 minutes than
lower dose of 173 minutes analgesia without any increase in side
effects.
16.Sen M (1992) studied intrathecal buprenorphine for post operative
analgesia in orthopaedic surgery. Intrathecally either hyperbaric
bupivacaine 1 ml in group A (30 cases) or bupivacaine 1 ml and
buprenorphine 300 micrograms in combination was given, only
minimal disturbance of consciousness and respiration were
observed. The only side effect of buprenorphine group was nausea
and vomiting in 10 patients.
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AIM OF STUDY
The primary aim of this study is to evaluate the onset, duration of
sensory and motor block, quality and duration of postoperative analgesia of
Magnesium sulphate and buprenorphine given intrathecally with
hyperbaric 0.5% bupivacaine in patients undergoing infraumbilical
surgeries.
The secondary aim of this study is to study the hemodynamic
changes & adverse effects related to the intervention.
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ANATOMY OF SPINE
The spinal canal extends from foramen magnum to sacral hiatus. It
is formed by the vertebral border inferiorly, pedicles by laterally and by
laminae and spines posteriorly.
SPINAL CORD
a) An elongated cylindrical mass of nervous tissue.
b) Length 42-45cm, weight – 30gm
c) Occupies upper 2/3rd of vertebral canal
d) Extends from atlas to L1 or L2 vertebra
e) The anterior and posterior roots of the most caudal nerves emerge
from the conical terminus of the spinal cord.
The distal termination of the spinal cord, because of the differential
growth rates between the bony vertebral canal and central nervous system
varies from L3 in the infant, to the lower border of L1or upper border of
L2 in the adult. Surrounding the spinal cord in the bony vertebral column
are three membranes (from within to the periphery), the piamater,
arachnoid mater and duramater. The piamater is a highly vascular
membrane that invests closely the spinal cord. The arachnoid mater is a
delicate neovascular membrane closely attached to the outermost
duramater. Between the two innermost membranes is the subarachnoid
space. In this space are the cerebrospinal fluid, spinal nerves, blood vessels
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that supply the spinal cord and the denticulate ligaments.The subarachnoid
space continues to S2.
The outermost membrane in the spinal canal is the longitudinally
organized fibroelastic membrane, the duramater. This layer is the direct
extension of the cranial duramater and extends as the spinal duramater
from the foramen magnum to S2, where the filum terminale blends with
the periosteum of the subdural space which contains only small amounts of
serous fluids to allow the duramater and arachnoid mater move over each
other.
Surrounding the duramater is the epidural space which extends from
the foramen magnum to the sacral hiatus. Posterior to the epidural space is
the ligamentum flavum. It extends from the foramen magnum to the sacral
hiatus. Ligamentum flavum extends from the anterior inferior aspect of the
lamina above to the posterior superior aspect of the lamina below.
Immediately posterior to the ligamentum flavum is the interspinous
ligament. Extending from the external occipital protuberance to the
coccyx, posterior to these structures is the supraspinous ligament. The
Lumbar puncture is routinely done below the L2 vertebrae down to the L5-
S1 intervertebral space to avoid damaging the spinal cord.
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CURVATURES OF THE SPINE
Cervical curve –anterior convexity
Dorsal curve – posterior convexity
Lumbar curve – anterior convexity
Sacrococcygeal – posterior convexity
High point of spinal curvature – L3
Lowest point - T5
Blood supply :
Blood supply to spinal cord is derived from a single anterior spinal
artery and two posterior spinal arteries. The anterior spinal artery is formed
from vertebral artery at base of the skull and it courses down along the
anterior surface of the cord. It supplies the anterior two-thirds of the spinal
cord, whereas the posterior spinal arteries supply the posterior one-third.
The posterior spinal arteries arise from the posterior inferior
cerebellar arteries and it courses down along the dorsal surface of the
spinal cord medial to the dorsal nerve roots.
Sub-arachnoid space :
Sub arachnoid space is located between the pia and arachnoid mater. It
includes the following structures :
(i) CSF
(ii) Spinal nerves
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(iii) A trabecular network between the membranes,
(iv) Blood vessels that supply the cord
(v) Lateral extension of the pia mater are the dentate ligaments .These
ligaments give lateral support from the spinal cord to the pia mater.
CEREBROSPINAL FLUID:
This is an ultrafiltrate of the blood plasma from choroid plexus of
the lateral ventricles with a pH of 7.32 (7.27-7.37)
It is a clear, colourless fluid found in the cranial and spinal subarachnoid
spaces and in the ventricles of the brain.
The total volume of CSF in an adult ranges from 120-150ml of
which 25-35ml is in the spinal subarachnoid space.
Composition of cerebrospinal fluid:
Specific gravity - 1.006 (1.003-1.009) at 370C
Pressure - 60-80mm of water
Pco2 - 48mmHg
HCo3- - 23meq/l
Na+ - 133-145meq/l
Ca+ - 2-3meq/l
Po4- - 1.6mg/dl
Mg+ - 2-2.5mg/dl
cl- - 15-20mg/dl
Protein - 23-38mg/dl
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Sugar - 45-80mg/dl
Lymphocytes - 0-5cells/cmm
An important factor that determines the spread of drug in
cerebrospinal fluid is the specific gravity of the drug in relation to that of
the cerebrospinal fluid (Baricity) which is 1.003-1.009. Hyperbaric
solution is a solution which is denser than CSF at 370C.
Planes between the surface of the skin and subarachnoid space
The needle used to perform a diagnostic spinal tap or a spinal anes thesia
needs to cross the skin, subcutaneous tissue, supraspinous ligament,
interspinous ligament, ligamentum flavum, duramater and arachnoid,
before reaching the subarachnoid space and CSF. The space between the
ligamentum flavum and duramater is the epidural space.
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SPINAL ANAESTHESIA
Definition: Spinal anaesthesia is a form of regional anaesthesia
obtained by blocking the spinal nerves in the sub arachnoid space by
injecting local anaesthetic solution in to CSF, which mainly act on the
spinal nerve roots.
Mechanism of Spinal Anaesthesia:
Injection of local anesthetic solution into the CSF allows access
to sites of action both within spinal cord and peripheral nerve roots.
The nerve roots which leave the spinal canal are not covered by epithelium
and are readily exposed to the local anesthetic within the CSF. Therefore
afferent impulses leaving via the ventral nerve roots are blocked during
spinal anesthesia. Local anesthetics block the sodium channels and
electrical conduction in spinal nerve roots. There are also multiple
potential actions of local anesthetics within the spinal cord at different
sites. Local anaesthetics can exert sodium channel block within the dorsal
and ventral horns, inhibiting generation and propagation of electrical
activity.
Differential Blockade
Sensory: In Subarachnoid block, sympathetic fibres are blocked two to
three segments higher than sensory fibres. Sympathetic block will be
greater when more concentrated solutions are used.
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Motor: In Subarachnoid block, motor fibres are blocked two segments
lower than sensory fibres.
The susceptibility of nerve fibre depends on
1. Fibre size
2. Degree of myelinisation and the distance between the nodes of
ranvier.
3. Frequency of nerve impulse transmission
Order of nerve blockade
1. Autonomic preganglionic b fibres
2. Temperature – cold first and then warmth.
3. Temperature discrimination
4. Slow pain followed by fast pain
5. Tactile sense
6. Motor blockade – extensors first then flexors
7. Pressure sense
8. Proprioception.
During recovery, return of sensibility in the reverse order was
assumed, but it has been suggested that sympathetic activity returns
before sensation.
FACTORS INFLUENCING HEIGHT OF BLOCKADE:
a - Site of injection
b - Angulation of needle
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c - Characteristic of local anaesthetic i.e baricity
d - Dose of local anaesthetic
e - Position of the patient during and after injection
f - Anatomical configuration of spinal column.
g - Patient height
h - Volume of cerebrospinal fluid
20
PHARMACOLOGY OF  BUPIVACAINE
Bupivacaine is an amide linked local anaesthetic. It is a
hydrochloride salt of d(1)-1-butyl N-(2’6’ dimethylphenyl) piperidine –
2 - carboxamide and is presented as a racemic mixture.
 It was synthesized by EO af Ekenstem.
 First reports of its use was published in 1963 by Telivuo.
 It is derived from Mepivacaine
 It is very stable compound and may be autoclaved repeatedly.
Pka is 8.1
MW - 288
Protein binding - 95%
Lipid solubility - 28
Elimination half life - 210 minutes
Toxic plasma concentration - >1.5μg/ml
Approximate duration of action- 175minutes
Availability:
Ampoule – Contains 0.5% Bupivacaine hydrochloride 4cc
0.5% Bupivacaine hydrochloride with dextrose (heavy) 4cc
Vials – Contains 0.25% and 0.5% Bupivacaine hydrochloride 20cc
Dosage - Maximum dosage 3mg/kg body weight.
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Uses:
1. Spinal anaesthesia
2. Epidural anaesthesia
3. Caudal anaesthesia
4. Continuous epidural anaesthesia
5. Peripheral nerve block
Site of action Onset(minutes) Duration(minutes)
Intrathecal 5 180-240
Epidural 15-20 165-225
Brachial plexus 15-20 600
Pharmacokinetics:
Once injected intrathecally, it gets absorbed by nerve rootlets and
results in the desired effect. It is rapidly absorbed from site of injection, but
the rate of absorption of the drug depends on the vascularity at the site and
the presence of vasoconstrictors. The high lipid solubility of bupivacaine
makes it easy for nerve and vascular tissue penetration. 80-95% of the
absorbed bupivacaive is bound to the plasma.
Excretion:
Bupivacaine is excreted through the kidney, 4-10% of the drug is
excreted unchanged.
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Mode of Action:
a) Site of action:
i) The spinal nerve rootlet fine nerve
ii) Posterior and lateral aspects of the spinal cord .
b) Sodium Channel blockade:
The local anaesthetics impede sodium ion access to the axon interior
by occluding the transmembrane sodium channels thus delaying the
process of depolarisation and axon remains polarized. It is a
nondepolarisation blockade.
Pharmacodynamics:
It has a longer duration of action but a slower onset of action.
Cardio vascular system:
It reduces the cardiac output by reducing the sympathetic tone and
by slowing the heart rate.
By reducing the venous return, it produces a fall in arterial blood
pressure, but it is relatively slow and is seldom very profound.
It also produces a fall in central venous pressure. It causes an
increase in blood flow in the lower limbs and there is a reduction in
incidence of deep vein thrombosis.
Respiratory System:
Spinal blockade can seldom happen, if ever causes respiratory
problem.
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Gastro intestinal tract:
There is an increase in gastro intestinal motility and gastric
emptying is increased.
Toxicity: Toxicity is related to the plasma level of the unbound drug and is
more likely due to an inadvertent intravenous injection. Systemic toxicity
reactions primarily involves the central nervous system and cardio vascular
system. The blood level required to produce central nervous system
toxicity is less than that required to produce circulatory collapse.
Central Nervous System Toxicity:
The objective signs are excitatory and includes shivering, muscle
twitching and tremor. Ultimately generalized tonic, clonic seizures occurs.
Cardiovascular System Toxicity:
The rate of depolarization in fast conducting tissue of purkinje fibres
and ventricular muscle is decreased. The rate of recovery of  bupivacaine
induced block is slower than that of lignocaine. Extremely high
concentration of the drug causes sinus bradycardia and cardiac arrest.
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PHARMACOLOGY OF BUPRENORPHINE
Buprenorphine is a semi synthetic highly lipophilic opioid derived
from thebaine, an opium alkaloid related to morphine, and is a long acting
analgesic with narcotic agonist and antagonist action. It is a white powder,
weakly acidic and with limited solubility in water.
Structural formula
Buprenorphine hydrochloride chemically is 17(cycloprophylmethyl)
α (1,1 dimethylethyl) -4-5 epoxy -18-19 dihydro-3 hydroxy 6 methoxy
αmethyl- 6, 14 –ethano –morphinan -7-methanol,hydrochloride(5,7(s)).
Molecular formula- C29H41NO4 HCl.
Molecular weight =504.09
Mechanism of Action
Buprenorphine appears to have a high affinity for both μ and ĸ
receptors and low to moderate intrinsic activity at μ and ĸ receptors.
It binds slowly with and dissociates slowly from the μ receptors.(this may
account for the prolonged duration of analgesia )
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CLINICAL PHARMACOLOGY
It is similar in structure to morphine but approximately 33 times
more potent. Whereas fentanyl dissociates rapidly from μ receptors (t½ of
6.8 minutes), buprenorphine has a higher affinity and takes much longer
(t½ of 166 minutes). The onset of action of buprenorphine is slow, its peak
effect may not occur until 3hours, and the duration of effect is prolonged
(<10 hours). The volume of distribution of buprenorphine is 2.8 L/kg, and
its clearance is 20 mL/kg/minute. Plasma concentrations of the metabolites
of buprenorphine (norbuprenorphine,buprenorphine-3-glucuronide, and
norbuprenorphine-3-glucuronide) may approximate or exceed those of
theparent drug. Glucuronide metabolites are biologicallyactive and may
contribute to the overall pharmacology of buprenorphine.
Effect on the CNS:
Buprenorphine produces analgesia, sedation, miosis and to a lesser
degree, nausea and vomiting .It may also produce side effects like
dizziness , sweating and headache.
Effect on respiratory system:
Buprenorphine depresses the respiratory centre and decreases both
the tidal volume and rate of respiration. It decreases minute ventilation at
doses higher than 3μg/kg but maximal respiratory depression is observed
only 3hours later. Respiratory depression can be prevented by prior
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administraton of naloxone,but it is not readily reversed once the effects
have been produced.
Pharmacokinetics:
Absorption :
Buprenorphine is relatively well absorbed by most routes including
the sublingual route. It is a highly lipophilic substance and is well absorbed
across biological membranes.
Protein binding:
It is highly protein bound, primarily to α and β globulin
fraction(96%). Volume of distribution is 2.8L/Kg.
METABOLISM:
Buprenorphine is metabolised in liver by N-dealkylation and
glucuronide conjugation and the metabolites are – Buprenorphine 3
glucuronide and Norbuprenorphine which have have lower affinity for the
μ receptors. Metabolites are excreted through bile in the faeces and a
smaller amount appears in the urine.
Clearance rate -20ml/Kg/min.
Preparation, Routes of administration and Doses :
It is available as clear, sterile solution for IV and IM administration
and each ml contains 0.324mg (equivalent to 0.3mg Buprenorphine) 50mg
anhydrous dextrose, water and HCl to adjust pH.
27
Preservative free Buprenorphine is available as 0.3mg/ml. It is also
available as sublingual tablets.
Therapeutic uses :
1. As premedication
2. As an analgesic
3. Post-operative analgesia
4. Acute pain of moderate to severe degree
5. Chronic pain
6. Sublingual buprenorphine in preventing recurrence of pain following MI
6. As adjuvant in Neuraxial blockade for intra and post-operative pain
relief.
Precautions:
1. It is to be used with caution in patients with COPD, corpulmonale,
hypoxia , hypercapnia
2. It is to be used with caution in head injury, intracranial lesions and in
circumstances where CSF pressure may be increased.
3. Patients receiving other narcotics, phenothiazines, sedatives, hypnotics
or other CNS depressants with Buprenorphine can exhibit an additive CNS
depression.
4. It should be cautiously used in elderly/ debilitated patients and those
with severe renal, hepatic and pulmonary impairment.
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5. It should be used with caution in myxoedema or hypothyroidism,
adrenocortical suppression,CNS depression, coma, acute alcoholism and
delirium tremens
Tolerance and physical dependence:
Extensive investigations in variety of animal species have identified
a very low physical dependence liability. This has been confirmed in
human volunteer studies (Jasinski D.B Pevink and Griffiths 1978)
following naloxone challenge and abrupt withdrawl after high dose chronic
administration of  buprenorphine by a subcutaneous route. It is considered
to have a low addictive potential .
Drug interactions:
Caution to be exercised when Buprenorphine is used in combination
with CNS depressant drugs and MAO inhibitors.
Pregnancy :
No major fetal malformation was noted when administrated via IM or
IV route.
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PHARMACOLOGY OF MAGNESIUM
It is a bivalent ion with an atomic weight of 24.312.
It is the fourth common mineral salt in the body after phosphorus,
calcium and potassium.
In serum, Mg is divided into three fractions-
1) Ionised,
2) Protein bound and
3) In anion complexes.
These fractions accounts for 65%, 27%, and 8% in serum concentration
respectively.
CHEMICAL STRUCTURE OF MAGNISIUM SULPHATE:
PROPERTIES OF MAGNESIUM SULPHATE:
1) CELLULAR PROPERTIES:
Magnesium intervenes in the activation of membrane Ca2+ ATPase
and Na+ K+ ATPase.It act as a stabilizer of cell membrane and
intracytoplasmic organelles.
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2) ION CHANNELS:
Mg2+ acts as a regulator of different ion channels. It has a
competitive antagonist action against calcium inflows. It limits the
outflow of calcium from the sarcoplasmic reticulum. So it is a Ca2+
channel blocker and Ca2+ channel modulator.
3) CARDIOVASCULAR SYSTEM:
It acts on calcium channels in the myocardium and also
actsnindirectly on the cardiac muscle by inhibiting the Ca2+ uptake on
the Troponin C of the myocytes and thereby it influences myocardial
contractility.The vasodilatory action of  Mg2+is due to its activation of
CAMP. This causes reduction in systolic blood pressure. Pulmonary
vascular resistance remains unaltered. Coronary vascular resistance is
reduced and hence causes vasodilation.
4) NEUROMUSCULAR TRANSMISSION:
Mg2+ has a preponderant presynaptic and postsynaptic effect.
Presynaptic release of acetylcholine is reduced by magnesium.
5) RESPIRATORY SYSTEM:
Mg2+ has a bronchodilator action due to the smooth muscle
contraction inhibition, inhibition of histamine release from mast cells
and acetylcholine release from cholinergic nerve endings..
6) Mg2+ acts as a NMDA receptor antagonist. This property explains
its use in post-operative analgesia.
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8) It increases the production of prostaglandins causing vasodilatation
of small intracranial vessels and this is responsible for its
anticonvulsant action.
CLINICAL USES:
1) Eclampsia- A loading dose of 4-6gm magnesium sulphate diluted in
100ml of normal saline given over 15min iv. 2 gm/hr in 100ml of IV
infusion is started thereafter. Serum levels should be maintained
between 4-7mEq/L.
2) Tocolytic effect at serum levels of 8-10mEq/L. Loading dose of 4-
6gm is given over 20min intravenously, then after the contraction
ceases, maintenance is done using 2-4gm/hour intravenously for 12-24
hours.
3) To reduce the intubation stress response, magnesium sulphate is used
in the dosage of 30-50mg/kg iv.
4) In surgery for phaeochromocytoma Mgso4 helps to maintain
haemodynamic balance as it inhibits the catecholamine release from
adrenal medulla and adrenergic nerve endings.
5) Nephritic Seizures: In children with nephritic seizures, the 50%
Mgso4 concentration should be diluted to a 20% solution for i.m.
injection. The dose for children is 0.1 to 0.2 mL of a 20% solution/kg of
body weight, administered i.m, to control seizures.
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6) It is used in the postoperative period of patients who have undergone
CABG to reduce the incidence of ventricular arrhythmias.
7) It is used in the treatment of Torsades De Pointes, either
intravenously or intraosseously in the dosage of 25 to 50 mg/kg (upto 2
gm).
8) Acute myocardial infarction: Mgso4 is used in the dose of 2gm iv
over 5-15 min followed by 18gm over 24hrs as infusion.
9) Total Parenteral Nutrition: In TPN, maintenance requirements for
magnesium are not known precisely. The maintenance dose
recommended for adults is 5-8 mEq /L of TPN solution. The daily adult
intake ranges from 10-24 mEq. In infants, the recommended intake
ranges from 0.25-0.6 mEq/kg/day.
10) In barium poisoning: 1-2gm of magnesium is used to counteract the
intense muscle stimulating effects of barium.
11) It is used for its bronchodilatory action in refractory asthma.
12) Hypomagnesemia- In cases of mild deficiency,1gm every 6 hours
for four doses and in severe deficiency, 1-5gms (2 – 10ml of 50%
solution) in divided doses, repeated until the serum levels are normal.
13) At a serum concentration of 2-4mEq/L, magnesium gives a good
control of spasms and muscle rigidity in Tetanus patients.
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MATERIAL AND METHODS
Study design- Prospective, Randomised, double blind study.
The study was conducted at Tirunelveli medical college hospital in 60
patients undergoing elective infraumbilical surgeries.
Sample size was estimated to be 60 based on previous studies based on
mean analgesia duration. Based on this, 30 patients in each group.
Formula used was n = (Zα/2+Zβ)2 *2*σ2 / d2,where , Zα/2 is the critical
value of the Normal distribution at α/2 (e.g. for a confidence level of 95%,
α is 0.05 and the critical value is 1.96), Zβ is the critical value of the
Normal distribution at β (e.g. for a power of 80%, β is 0.2 and the critical
value is 0.84), σ2 is the population variance, and d is the difference you
would like to detect.
Patients were allocated into two groups, group B and group M, by
sequential randomization.
GROUP B (n=30): Patients in this group received 3ml of 0.5% hyperbaric
bupivacaine + 0.5ml (150µg) buprenorphine to a total volume of 3.5ml.
GROUP M (n=30) : Patients in this group received 3ml (15mg)of 0.5%
hyperbaric bupivacaine + 0.5ml (50mg) magnesium sulphate to a total
volume of 3.5ml.
The Institutional Ethical Committee approval was obtained.
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Inclusion Criteria
Age 18 and above
ASA - I and II patients
BMI - >30 kg/m2
Patients undergoing infraumbilical surgeries.
Exclusion criteria
Contraindication to regional anesthesia
Hypersensitivity  to the study drugs
Renal or hepatic  dysfunction
Uncontrolled labile hypertension
Diabetes  mellitus
Coagulopathy
The procedure was explained to the patients and informed consent
was obtained. The height, weight were recorded on the day of
surgery.
Preoperative evaluation
Patients who were included in the study had a proper history taken
and clinical examinations of their cardiovascular and respiratory system.
The investigations done included, complete blood count, Blood Urea,
creatinine and sugar, Urine albumin and sugar, ECG, chest xray to rule out
any systemic illness.
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Basic monitoring like pulse oximeter, ECG, NIBP connected to the patient.
Baseline status consisting of  Pulse rate, systolic and diastolic blood
pressure, respiratory rate, oxygen saturation were recorded on arrival at
OT. Preloaded was done with 20ml/kg RL prior to administering sub-
arachnoid block.
Blinding was achieved with the use of equal amount of drugs (3.5
ml), and the syringes used were labeled as B and M. Identical coded
syringes, prepared by persons not involved in the study, were randomly
handed over to the anaesthesiologists unaware of the identities of the drug.
Volumes of the drug, size of the syringe, colour of drug of interest were
similar in the two groups. The final volume of injected solutions was 3.5ml
in the two groups.
Ampoules of 0.5% hyperbaric bupivacaine, buprenorphine 300μg/cc
magnesium sulphate 50% were used for the study With aseptic
precautions, lumbar puncture was performed in the lateral decubitus
position, through midline approach using a Quincke 25 gauge lumbar
puncture needle inserted through the L3 – L4 inter vertebral space. Patients
in group M received 3ml of 0.5% heavy bupivacaine + 0.5ml of 50%
magnesium sulphate (50mg). 1ml of 50% Mgso4 [500mg] was diluted to
5ml and 0.5ml of this solution was taken. Patients in group B received 3ml
of 0.5 % heavy bupivacaine + 150μg of buprenorphine (0.5ml). The total
drug volume in the two groups were same (3.5ml).The drugs were loaded
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by an independent colleague. The patient and the anaesthesiologist were
blinded to the procedure.The patients were made supine immediately after
injection of the drug. Standard monitoring carried out in the perioperative
period included electrocardiography, non-invasive arterial blood
pressure,respiratory rate monitoring and pulse oximetry.
The time of intrathecal injection, time taken for onset of T10 analgesia,
time taken to attain maximal level of sensory block, time taken for two
segment sensory regression, duration of sensory block, time of onset of
complete motor block, duration of total spinal anaesthesia and duration of
effective analgesia were recorded.
Onset of analgesia was defined as the time taken from intrathecal
injection to time taken to obtain T10 analgesia. Onset and recovery of
motor block were assessed using modified bromage scale. Duration of
spinal anaesthesia was defined as time taken from intrathecal injection to
the first complaint of pain. Duration of effective analgesia was defined as
time taken from intrathecal injection to the time of first analgesic request.
SENSORY BLOCK
The onset of sensory block was defined as time between the
injection of intrathecal anaesthetic solution and the absence of pain at the
T10 dermatome. Sensory block was assessed by loss of pinprick sensation
using 21 gauge sterile needles bilaterally along mid clavicular line.
Assessment was started immediately after turning the patient supine and
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was continued every minute till loss of sensation to pinprick at T10 level
was noted. This was continued until the peak block height was reached and
this time was noted. The duration of  two segment regression was taken as
the time for regression of two segments from the maximum block height
which was evaluated by pin prick. Sensory block was checked every
15min till it reached 2 segment regression levels.
MOTOR BLOCK
Motor block was assessed bilaterally using the Modified bromage
scale.
MODIFIED BROMAGE SCALE.
0 - No block. Patient able to raise extended legs against gravity.
1 – Patient unable to raise extended leg, but just able to flex knees.
2 – Patient unable to flex knees but able to flex ankle.
3 - Total block.Complete inability to flex ankle / move leg.
Immediately after the patient was turned supine, the
assessment of motor block was done and it was continued every
minute until bromage score of  3 was reached. Onset of motor block
was defined as time to achieve bromage score of 3 from time of
intrathecal injection. Duration for complete motor block recovery
was taken as time from intathecal injection to return of bromage
score of  0.
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VITAL SIGNS AND SIDE EFFECTS
Systolic and diastolic blood pressure, pulse rate and Spo2 were
recorded for every 2 mins for the first 10 mins and thereafter every 5 mins
until the immediate postoperative period. Hypotension was defined as fall
in systolic blood pressure >20 % from baseline or SBP <90 mm Hg. This
was managed with IV ephedrine.
Bradycardia (HR< 60 / min) if present was planned to be managed
with intravenous atropine in incremental doses.
Respiratory depression was said to be present if RR< 8 per minute
and or SpO2 <85 %. This was planned to be managed with mask
ventilation or intubation and IPPV. Vomiting, if present, was planned to be
managed with Inj.Ondansetron 8 mg iv.Pruritis, if present, was planned to
be managed with reassurance or inj.Pheniramine maleate iv.
Urinary retention was monitored postoperatively. Catheterization
was planned in patients with retention for more than 6 hours.
Motor block was assessed till bromage score of 0 was reached.
Inj. Diclofenac sodium 75 mg or Inj tramadol 100mg was given im
as the rescue analgesic when patient complained of pain and VAS score
was >4.
Patients were monitored for 24 hours to detect side effects like
respiratory depression, nausea, vomiting, pruritus, shivering etc.
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STATISTICAL ANALYSIS
The results were analysed SPSS package (version 21.0) using
(Statistical Package for Social Sciences). The results are represented
as mean and standard deviation. Mann Whitney U test and Kruskal
Wallis test was used for categorical data.For parametric data,
unpaired t test was used. Results were considered statistically
significant if p-value<0.05.
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OBSERVATIONS AND RESULTS
The confounding factors which can affect the results were
statistically compared between the two groups and were found to be
similar.
The mean time of onset of analgesia to T10 was 6.98 minutes in the
magnesium group, 4.91 minutes in the buprenorphine group .The mean
time of onset of complete motor block was 6.65 minutes in the magnesium
group, 4.56 minutes in the buprenorphine group.
The onset of analgesia and complete motor block were significantly
delayed in the magnesium group compared to the buprenorphine group.
With respect to highest level of sensory block achieved, the median was T6
in buprenorphine group and T8 in magnesium group. The range was T4 –
T8 in magnesium T4-T7 in buprenorphine group. On pair wise comparison
the difference in levels obtained was found to be significant between
buprenophine and magnesium.
The mean time to attain maximum level of sensory block was 10.32
minutes in the magnesium group, 6.96 minutes in the buprenorphine
group.The time taken to achieve maximum sensory level was significantly
delayed in the magnesium group compared to buprenorphine group. In the
present study, the mean duration of regression of sensory block by two
segments, from the highest level attained, was 136.17 minutes in the
magnesium group, it was 145.27 minutes in the buprenorphine group .The
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difference in mean values was found to be significant between
buprenorphine and magnesium group.
The mean duration of spinal anaesthesia was 171.63 minutes in the
magnesium group and  229.43 minutes in the buprenorphine group The
difference in mean values was found to be significantly prolonged in
buprenorphine group compared to magnesium group. In our study, the
mean duration of effective analgesia was 280.3 minutes in the magnesium
group, 481 minutes in the buprenorphine .The differences in mean values
were found to be significant.
Comparison of the parameters observed between the two groups
Groups Magnesium (M) Buprenorphine
(B)
p value
Time to T10 analgesia 6.98 4.91 <0.001
Onset of complete motor
block
6.65 4.56 <0.001
Time to maximum sensory
block
9.36 5.93 0.028
Maximum sensory level T4 T6 0.028
Time to 2 segment
regression of sensory
block
136.17 145.27 <0.001
Duration of total analgesia 170.13 230.3 <0.001
Duration of effective
analgesia
280.33 481 <0.001
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GROUPS
TABLE 1
GROUP NO OF PATIENTS PERCENTAGE
BUPRENORPHINE 30 50%
MAGNESIUM SULFATE 30 50%
50%50%
GROUP
BUPRNORPHINE
MAGNESIUM SULFATE
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GROUP PARAMETERS
TABLE 1.1
PARAMETERS MEAN SD
AGE 32.03 9.46
WEIGHT 53.03 8.9
HEIGHT 158.38 6.43
TIME TO MAXIMUM SENSORY
BLOCK
7.65 1.79
ONSET OF COMPLETE MOTOR
BLOCK
5.6 1.17
TIME TO SEGMENTAL REGRESSION
OF SENSORY BLOCK
140.72 7.44
TIME TO T10 ANALGESIA 5.95 1.09
DURATION OF SURGERY 74.17 11.13
DURATION OF EFFECTIVE
ANALGESIA
380.67 105.63
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AGE DISTRIBUTION
TABLE 2
AGE IN YEARS NO OF PATIENTS PERCENTAGE
<30 32 53%
31-40 16 27%
>40 12 20%
53%
27%
20%
AGE DISTRIBUTION
<30
31-40
>40
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TABLE 2.1
29
.93
34
.13
B U P RENORPH INE MAGNES IUM  SU L FA T E
me
an
 ag
e i
n y
ea
rs
MEAN AGE IN YEARS
GROUP
AGE IN YEARS
MEAN SD
BUPRENORPHINE 29.93 9.01
MAGNESIUM SULFATE 34.13 9.58
UNPAIRED T TEST
P VALUE - 0.086
NON SIGNIFICANT
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SEX DISTRIBUTION
TABLE 3
SEX NO OF PATIENTS PERCENTAGE
MALE 29 48%
FEMALE 31 52%
48%52%
SEX
MALE
FEMALE
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TABLE 3.1
GROUP
SEX
MALE FEMALE
BUPRENORPHINE 16 14
MAGNESIUM SULFATE 13 17
MANN WHITNEY U TEST
P VALUE - 0.438
NON SIGNIFICANT
16
131
4
17
B U P RENORPH INE MAGNES IUM  SU L FA T E
SEX
 DI
STR
IBU
TIO
N
SEX DISTRIBUTION
SEX MALE SEX FEMALE
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WEIGHT
TABLE 4
WEIGHT NO OF PATIENTS PERCENTAGE
<50 KG 28 47%
>50 KG 32 53%
47%
53%
WEIGHT
<50 KG
>50 KG
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TABLE 4.1
GROUP
WEIGHT
MEAN SD
BUPRENORPHINE 53.23 10.49
MAGNESIUM SULFATE 52.83 7.15
UNPAIRED T TEST
P VALUE - 0.864
NON SIGNIFICANT
53
.23
52
.83
B U P RENORPH INE MAGNES IUM  SU L FA T E
ME
AN
 W
EIG
HT
MEAN WEIGHT
50
HEIGHT
TABLE 5
HEIGHT NO OF PATIENTS PERCENTAGE
< 160 CM 38 63%
> 160 CM 22 37%
63%
37%
HEIGHT
< 160 CM
> 160 CM
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TABLE 5.1
15
7.8
7
15
8.9
B U P RENORPH INE MAGNES IUM  SU L FA T E
ME
AN
 HE
IGH
T
MEAN HEIGHT
GROUP
HEIGHT
MEAN SD
BUPRENORPHINE 157.87 6.91
MAGNESIUM SULFATE 158.9 5.99
UNPAIRED T TEST
P VALUE - 0.539
NON SIGNIFICANT
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TIME FOR MAXIMUM SENSORY BLOCK
TABLE 6
TIME FOR MAX SENSORY
BLOCK
NO OF
PATIENTS
PERCENTAG
E
< 8 MIN 30 50%
> 8 MIN 30 50%
30 30
0
5
10
15
20
25
30
35
< 8 MIN > 8 MIN
TIME FOR MAXIMUM SENSORY BLOCK
NO OF PATIENTS
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TABLE 6.1
GROUP
TIME FOR MAXIMUM SENSORY BLOCK
MEAN SD
BUPRENORPHINE 5.93 0.31
MAGNESIUM SULFATE 9.36 0.58
UNPAIRED T TEST
P VALUE - 0.001
SIGNIFICANT
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ONSET OF COMPLETE MOTOR BLOCK
TABLE 7
ONSET OF COMPLETE MOTOR
BLOCK
NO OF
PATIENTS
PERCENTA
GE
< 6 MIN 40 37%
> 6 MIN 20 33%
67%
33%
ONSET OF COMPLETE MOTOR BLOCK
< 6 MIN
> 6 MIN
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GROUP
ONSET OF COMPLETE MOTOR BLOCK
MEAN SD
BUPRENORPHINE 4.56 0.52
MAGNESIUM SULFATE 6.65 0.55
UNPAIRED T TEST
P VALUE - 0.001
SIGNIFICANT
TABLE 7.1
TABLE 7.1
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MAXIMUM SENSORY LEVEL
TABLE 8
MAXIMUM SENSORY LEVEL NO OF PATIENTS PERCENTAGE
T4 16 27%
T5 13 22%
T6 25 41%
T7 5 8%
T8 1 2%
27%
22%
41%
8%2%
MAXIMUM SENSORY LEVEL
T4
T5
T6
T7
T8
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MAXIMUM SENSORY
BLOCK
GROUP
BUPRENORHINE
MAGNESIUM
SULFATE
T4 15 1
T5 3 10
T6 11 14
T7 1 4
T8 0 1
KEUSKAL WALLIS TEST
P VALUE - 0.001
SIGNIFICANT
TABLE 8.1
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TIME FOR SEGMENTAL REGRESSION OF SENSORY BLOCK
TABLE 9
TIME FOR SEGMENT REGRESSSION OF
SENSORY BLOCK
NO OF
PATIENTS
PERCENT
AGE
< 140 MIN 36 60%
> 140 MIN 24 40%
60%
40%
TIME FOR SEGMENT REGRESSION OF
SENSORY BLOCK
< 140 MIN
> 140 MIN
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TABLE 9.1
GROUP
TIME FOR SEGMENT REGRESSION OF
SENSORY BLOCK
MEAN SD
BUPRENORPHINE 145.27 7.05
MAGNESIUM
SULFATE
136.17 4.5
UNPAIRED T TEST
P VALUE - 0.001
SIGNIFICANT
145.27
136.17
130
132
134
136
138
140
142
144
146
BUPRENORPHINE MAGNESIUM SULFATE
TIME FOR SEGMENT REGRESSION OF
SENSORY BLOCK
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TIME FOR T10 ANALGESIA
TABLE 10
TIME FOR T10 ANALGESIA NO OF PATIENTS PERCENTAGE
< 6 MIN 31 52%
> 6 MIN 29 48%
52%48%
TIME FOR T10 ANALGESIA
< 6 MIN
> 6 MIN
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TABLE 10.1
GROUP
TIME TO T10 ANALGESIA
MEAN SD
BUPRENORPHINE 4.91 0.18
MAGNESIUM SULFATE 6.98 0.42
UNPAIRED T TEST
P VALUE - 0.001
SIGNIFICANT
4.91
6.98
0
1
2
3
4
5
6
7
8
BUPRENORPHINE MAGNESIUM SULFATE
TIME TO T10 ANALGESIA
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ASA GRADING
TABLE 11
ASA GRADE NO OF PATIENTS PERCENTAGE
ONE 32 53%
TWO 28 47%
53%
47%
ASA GRADE
ONE
TWO
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GROUP
ASA
ONE TWO
BUPRENORPHINE 15 15
MAGNESIUM SULFATE 17 13
UNPAIRED T TEST
P VALUE - 0.604
NON SIGNIFICANT
TABLE 11.1
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DURATION OF SURGERY
TABLE 12
DURATION OF SURGERY NO OF PATIENTS PERCENTAGE
< 75 MIN 39 65%
> 75 MIN 21 35%
65%
35%
DURATION OF SURGERY
< 75 MIN
> 75 MIN
65
72
.5
75
.83
B U P RENORPH INE MAGNES IUM  SU L FA T E
DU
RA
TIO
N O
F S
UR
GE
RY
DURATION OF SURGERY
GROUP
DURATION OF SURGERY
MEAN SD
BUPRENORPHINE 72.5 9.53
MAGNESIUM SULFATE 75.83 12.46
UNPAIRED T TEST
P VALUE - 0.249
NON SIGNIFICANT
TABLE 12.1
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DURATION OF TOTAL ANALGESIA
TABLE NO 13
DURATION OF TOTAL
ANALGESIA
NO OF
PATIENTS
PERCENTAG
E
>250 MIN 32 54%
<250 MIN 27 46%
54%
46%
DURATION OF TOTAL ANALGESIA
>250min
<250min
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TABLE NO 13.1
230.3
170.13
0
50
100
150
200
250
BUPRENORPHINE MAGNESIUM SULPHATE
MEAN DURATION OF TOTAL ANALGESIA
BUPRENORPHINE
MAGNESIUM SULPHATE
GROUP
DURATION OF TOTAL ANALGESIA
MEAN SD
BUPRENORPHINE 230.3 45.42
MAGNESIUM SULFATE 170.13 34.42
UNPAIRED T TEST
P VALUE - 0.001
SIGNIFICANT
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TABLE NO 14
DURATION OF EFFECTIVE ANALGESIA
DURATION OF EFFECTIVE
ANALGESIA
NO OF
PATIENTS
PERCENTAG
E
< 400 MIN 31 52%
> 400 MIN 29 48%
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TABLE 14.1
GROUP
DURATION OF EFFECTIVE ANALGESIA
MEAN SD
BUPRENORPHINE 481 36.13
MAGNESIUM SULFATE 280.33 23.85
UNPAIRED T TEST
P VALUE - 0.001
SIGNIFICANT
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SIDE EFFECTS
TABLE 15
SIDE EFFECTS BUPRENORPHINE MAG.SO4
HYPOTENSION 7 10
NAUSEA 0 0
VOMITTING 0 0
PRURITIS 0 0
SHIVERING 4 7
SEDATION 0 0
RESPIRATORY DEPRESSION 0 0
7
0 0 0
4
0 0
10
7
0
2
4
6
8
10
12
SIDE EFFECTS
BUPRENORPHINE MAG.SO4
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DISCUSSION
Spinal anaesthesia is the primary anesthetic technique for many
types of surgery. The recent developments in spinal anaesthesia has led to
greater patient satisfaction and faster functional recovery. Currently, new
methods of decreasing post-operative analgesic requirements are of high
interest. The use of local anaesthetics like bupivacaine has been unable to
provide analgesia for a longer duration. Most patients require further
analgesia during the post-operative period. Various adjuvants are added to
the intrathecal local anaesthetics for this purpose.
Buprenorphine is a lipid soluble drug and rapid absorption into the
spinal venous plexus allows minimal increase in spinal fluid concentration
with minimal risk of respiratory depression associated with rostral
spread[34].Buprenorphine has a high affinity for narcotics receptors and
therefore produces longer duration of analgesia compared to other
agents[26]. In the present study buprenorphine was chosen for comparison
as the prolongation of spinal analgesia by buprenorphine is quite well
studied [2and18] and hence it can be used as an active control to acertain
the efficacy of magnesium sulphate.
The safety of intrathecal Mgso4 has been studied in animal models.
The earlier studies had encouraged the use of intrathecal magnesium, but
the concurrent animal research [9-12] which were published recently have
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raised questions regarding the safety of intrathecal magnesium. However,
intrathecal mgso4 has been used in a significant number of humans and no
documented nurological complications were found.[13] Histopathological
and ultrastructural human spinal cord studies sound interesting but are
practically next to impossible. Due to such circumstances, the off label use
of intrathecal magnesium is supposed to thrive because of its availability,
affordability and advantages.
The optimum dose and concentration of  intrathecal magnesium for
its antinociceptive action is an untrodden area in research. In the first study
conducted in humans, [7] with intrathecal magnesium, the dose was fluked
out from within the safety range that was extrapolated from animal studies.
Magnesium has been used in different doses either alone or along with
lipophilic opioids.[1].It is not associated with pruritus, respiratory
depression, sedation etc, unlike opioids [8]. Recently,a few studies [8, 14-
17] have used higher doses of magnesium and have shown antinociceptive
action but the regression analysis of the dose response relationship has not
been performed and hence there is still scope for further higher doses. The
lowest dose studied of magnesium [5] which showed antinociceptive
potential was 50mg and hence it was used in our study.
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MOTOR BLOCKADE
In this study, magnesium significantly prolonged the onset of
complete motor block. The difference between mean time of onset of
complete motor block was 2.09 minutes (Mg vs buprenorphine). This
delayed onset can be due to difference in pH or baricity of the injected
solution. [19] Our study results are similar with those done by Paul et al
[5], Shukla et al [20] and Khezri et al [21].They demonstrated a delay in
onset of motor block by using 50mg of magnesium sulphate. The
difference in mean values of onset of sensory block and complete motor
block obtained by Khezri was 3.16 minutes and 4.37 (Mg vs control)
respectively which is nearly similar to our results. Studies done by Sanad
et al [23] and Khezri et al [21] and have demonstrated that 50mg of
intrathecal magnesium does not affect duration of motor block but Shukla
et al [20] using a similar dose contrasted these results. In both human and
animal studies, intrathecal magnesium sulphate has produced spinal
anaesthesia including motor blockade, but the dose which was used was
extremely high and the mechanism of action could not be elucidated [24].
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SENSORY BLOCKADE
In this study, intrathecal magnesium sulphate did not prolong
duration of sensory block like buprenorphine. The difference between
mean time of onset of maximum sensory blockade was 3.43 minutes (Mg
vs buprenorphine).The difference between mean time of onset of  T10
analgesia was 2.07 minutes (Mg vs buprenorphine).This difference in onset
can be due to difference in ph or baricity of the injected solution.
Magnesium also did not prolong the duration of 2 segment regression of
sensory block unlike buprenorphine. The difference between mean time to
2 segment regression of sensory block was 9.1 minutes (Mg vs
buprenorphine). Results similar to this were obtained in the study done by
Khezri et al [21]. The NMDA channels are involved in pain modulation
and hence NMDA blockers may not be expected to prolong sensory block.
But it has been shown that intrathecal injection of a large dose of
magnesium sulphate (1260 mg) causes a complete sensory and motor
lasting for 60 minutes[22]. However, the mechanisms weren’t elucidated.
Sanad et al [23] showed in his study that 50mg of magnesium prolonged
the regression of sensory block. However, a satisfactory explanation for
this prolongation cannot be suggested and hence, further studies and
clinical trials are required.
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The prolongation of sensory recovery in buprenorphine is attributed
to the clinical action of local anaesthetic and opioids are additive only after
some time has elapsed following intrathecal administration. This is due to
the time taken by the opioid from CSF to penetrate the deeper layer
(substantia gelatinosa) where opioid receptors are present. In our study
time for two dermatomal regressions was increased in Buprenorphine
group. Khan F[32] in his study showed that duration of sensory block was
significantly longer in buprenorphine-bupivacaine group.
DURATION OF SPINAL ANAESTHESIA
Magnesium did not prolong the duration of spinal anaesthesia like
buprenorphine in this study. The difference between mean duration of
spinal anaesthesia was 60 minutes (Mg vs buprenorphine). Similar results
to this, were obtained in the studies done by Khezri et al [20] and
Jabalameli et al [15]. Jabalameli showed that 75mg and 100 mg (higher
doses) of magnesium caused prolongation of spinal anaesthesia. But in the
study conducted by Khalili [14] 100mg of magnesium did not cause
prolongation of spinal anaesthesia. Morrison et al [1] recently did a meta-
analysis on the effect of intrathecal magnesium sulphate ± LA ± lipophilic
opioids. They commented that there is a lack of evidence in subgroup
analysis (magnesium added to LA alone) to support this prolongation.
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DURATION OF EFFECTIVE ANALGESIA
In this study, the duration of effective analgesia was significantly
prolonged in the buprenorphine group than in the magnesium group. The
difference in mean duration of effective analgesia was 200.67 minutes.
Similar results to this were obtained by Paul et al [5] and Sanad et al [23]
using 50mg of Mgso4. But, Khezri [21] et al showed that 50mg intrathecal
magnesium did not prolong the duration of effective analgesia. They
conducted this study in patients undergoing surgery for fracture femur and
perhaps the role of magnesium in preemptive analgesia was overlooked
and might have led to negative results. However they did demonstrate a
reduction in post operative opioid consumption with the use of intrathecal
magnesium. The actual duration of prolongation was around 78.93
minutes.
Capogna G et al [34] found excellent sensory analgesia for average
183 min to 430 min respectively. Celleno D[29 ] noted buprenorphine had
a longer pain-free interval for average 420 min. Sen M[28] noted duration
of effective postoperative analgesia was 190 min. Khan F[32] found
patients did not required postoperative analgesia in the first twenty four
hours in group B. Chansoriya KP et al[33], Rudra A[25], Thomas W[30]
have studied patients receiving buprenorphine had excellent pain relief.
Wang C[27], in his study confirms the limited ceiling effect of
buprenorphine on nociceptive reflexes. Rudra A[25] concluded that the
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analgesia was twice using buprenorphine in dose of 150 mcg than using it
as 100 mcg.
HAEMODYNAMIC CHANGES
In this study, the variations in pulse rate, blood pressure and
respiratory rate were comparable in both the groups. The differences were
not statistically significant thus proving that intrathecal magnesium is
hemodynamically stable. Katiyar et al in his study [17] found that 100mg
of intrathecal Mgso4 was associated with better haemodynamic stability
when compared to 25μg of intrathecal fentanyl. Other studies conducted by
Shukla D [20] and Khezri MB[21] also showed similar findings.
There was no significant variation in the intraoperative and
postoperative pulse rate, Systolic Blood pressure, respiratory rate and
SPO2% in both groups. No case of bradycardia was recorded. Spinal
anaesthesia induced hypotension is supposed to be due to sympathetic B
fibres causing pooling of blood in inferior extremity leading to reduced
cardiac output hence reduced systolic blood pressure.
Wang C. et al[27 ] have shown that intrathecal buprenorphine acts
on Aδ and C fibres without any effect on sympathetic outflow. These
observations in previous study by Chansoriya KP[33], Capogna G et
al[34], Celleno D et al[29], Rudra A et al[25], Sen M[28], Thomas W et al
[30] Lata R.K. et al[31] and Khan F [32] also found the same results
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regarding haemodynamic variables after addition of buprenorphine to
bupivacaine.
SIDE EFFECTS
The incidence of complications in this study was minimal. Studies
conducted using 50mg of intrathecal magnesium did not show any
increased incidence of complications[5,14,19,20and22]. Jabalameli et al
[15] showed that 100mg of intrathecal Mgso4 is associated with increased
incidence of intraoperative and postoperative complications like
hypotension, vomiting, nausea compared with lower doses. However they
didn’t find any difference in requirements of ephedrine or atropine
According to Capogna G[34], Sen M[28] the only side-effect found
due to buprenorphine group was nausea and vomiting. While Rudra A[25]
had not noted any side effects in patients. Celleno D et al [29], Lata R.K. et
al [31] and Thomas W et al [30] also studied intrathecal buprenorphine in
various doses observed rise in incidence of nausea and vomiting but
statistically not significantly (P>0.05) different than other drug used. It is
likely that highly lipophilic opioids when administered intrathecally at the
lumbar level to reach the chemoreceptor trigger zone in concentration
sufficient to directly induce nausea and vomiting.
Buprenorphine due to high lipid solubility and slow receptor
dissociation, once bound to spinal opioids receptors is responsible for
prolonging post-operative analgesia. It potentiates the action of spinal
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anaesthetic agents. The synergism is characterized by enhanced somatic
analgesia without effect on the degree or level of local anaesthetic induced
sympathetic or motor blockade.
The present study has a few limitations. A bigger sample size could
have been taken which would have resulted in lesser sampling bias.
Postoperative opioid consumption was not compared between the groups.
VAS scores in the late postoperative period (more than 8 hours) couldn’t
be compared.
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SUMMARY
We conducted a double blinded randomized controlled study in 60
patients belonging to ASA I and II undergoing elective infraumbilical
surgeries to evaluate the onset, duration of sensory and motor block,
quality and duration of postoperative analgesia of MAGNESIUM
SULPHATE and BUPRENORPHINE given intrathecally with hyperbaric
0.5% bupivacaine.
For the same reason, we divided randomly the patients into two
groups of 30 each.
Group B received 3 ml 0.5% bupivacaine (15 mg) and 0.5 ml
buprenorphine (150 mcg).
Group M received 3 ml 0.5% bupivacaine (15 mg) and 0.5 ml
magnesium sulphate (50 mg).
The total volume of the injected solution was 3.5 ml in both the
groups.
The onset of sensory and motor blockade, time to T10 analgesia,
maximum sensory level, two segment regression, the duration of sensory
and motor blockade and the duration of analgesia were noted in both
groups.
Demographic data obtained were similar in both the groups.
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We found that the onset of sensory and motor blockade was
prolonged in the magnesium group. The duration of sensory blockade, two
segment regression of sensory block, and duration of total analgesia was
prolonged in the buprenorphine group than magnesium group.
The duration of effective analgesia was prolonged in the
buprenorphine group than the magnesium group.
The incidence of side effects were almost similar in both the groups.
82
CONCLUSION
This study concludes that, the intrathecal administration of 150µg of
buprenorphine with bupivacaine has a significant faster onset of sensory
and motor blockade than magnesium sulphate. Intrathecal magnesium
sulphate, 50mg also significantly prolonged the time for first analgesic
request, but to a lesser extent than buprenorphine. So, magnesium sulphate
can also be used for prolongation of post operative analgesia.
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PROFORMA
A COMPARATIVE STUDY BETWEEN INTRATHECAL MAGNESIUM
SULPHATE AND BUPRENORPHINE AS ADJUVANTS TO HYPERBARIC
BUPIVACAINE FOR POST OPERATIVE ANALGESIA IN INFRAUMBILICAL
SURGERIES
PATIENT PARTICULARS
1. DATE
2. NAME
3. AGE
4. SEX
5. IP NO
6. HEIGHT
7. WEIGHT
8. DIAGNOSIS
9. SURGERY
PREANAESTHETIC EVALUATION
1. HISTORY
2. NIL ORAL FROM
3. PR
4. BP
5. CVS
6. RS
7. OTHER SYSTEMS
8. AIRWAY
9. ASA GRADE
10.ANAESTHESIOLOGIST
11.SURGEON
INVESTIGATIONS
1. HB
2. URINE
3. ALBUMIN
4. SUGAR
5. BLOOD SUGAR
6. UREA
7. CREATININE
 CXR
 ECG
 PRELOADING
INTRATHECAL INJECTION
1. POSITION
2. INTERSPACE
3. NEEDLE
4. TIME OF INJECTION OF ANAESTHETIC SOLUTION
5. ONSET OF SENSORY BLOCK AT T10
6. PEAK SENSORY LEVEL
7. TWO SEGMENT REGRESSION TIME
8. ONSET OF MOTOR BLOCK
9. DURATION OF TOTAL ANALGESIA
10.DURATION OF EFFECTIVE ANALGESIA
INTRAOPERATIVE MONITORING
1. PR
2. BP
3. SPO2
4. DRUGS
5. EVENTS
6. IV FLUIDS
 POSTOPERATIVE MONITORING
TIME
IN
MINS
0 15 30 45 60 120 180 240 300 360 420 480
PR
BP
SPO2
VAS
 SIDE EFFECTS
PRURITIS
NAUSEA AND VOMITING
RESPIRATORY DEPRESSION
HYPOTENSION
SEDATION
SHIVERING
 SUPERVISING ANAESTHESIOLOGIST
 PROFESSOR AND HOD
NehahspfSf;F mwptpg;G kw;Wk; xg;Gjy; gbtk; 
(kUj;Jt Ma;tpy; gq;Nfw;gj;w;F) 
Ma;T nra;ag;gLk; jiyg;G:  
gq;F ngWthpd; ngaH: 
gq;F ngWthpd; taJ: 
  gq;F ngWth; 
,jid  
Fwpf;fTk; 
1.  ehd; NkNy Fwpg;gpl;Ls;s kUj;Jt Ma;tpd; tptuq;fis gbj;J 
Ghpe;J nfhz;Nld;. vd;Dila re;Njfq;fis Nfl;fTk;> 
mjw;fhd jFe;j tpsf;fq;fis ngwTk; tha;g;gspf;fg;gl;Ls;sJ 
vd mwpe;J nfhz;Nld;. 
 
2.  ehd; ,t;tha;tpy; jd;dpr;irahf jhd; gq;Nfw;fpNwd;. ve;j 
fhuzj;jpdhNyh ve;j fl;lj;jpYk;> ve;j rl;l rpf;fYf;Fk; 
cl;glhky; ehd; ,t;tha;tpy; ,Ue;J tpyfp nfhs;syhk; vd;Wk; 
mwpe;J nfhz;Nld;. 
 
3.  ,e;j Ma;T rk;ge;jkhfNth> ,ij rhHe;J NkYk; Ma;T 
Nkw;fhs;Sk; NghJk; ,e;j Ma;tpy; gq;FngWk; kUj;JtH 
vd;Dila kUj;Jt mwpf;iffis ghHg;gjw;F vd; mDkjp 
Njitapy;iy vd mwpe;J nfhs;fpNwd;. ehd; Ma;tpy; ,Ue;J 
tpyfpf; nfhz;lhYk; ,J nghUe;Jk;; vd mwpfpNwd;. 
 
4.  ,e;j Ma;tpd; %yk; fpilf;Fk; jftiyNah> KbitNah 
gad;gLj;jpf; nfhs;s kWf;f khl;Nld;. 
 
5.  ,e;j Ma;tpy; gq;F nfhs;s xg;Gf; nfhs;fpNwd; vdf;F 
nfhLf;fg;gl;lmwpTiufspd; gb ele;J nfhs;tJld;> Ma;it 
Nkw;nfhs;Sk; kUj;Jt mzpf;F cz;ikAld; ,Ug;Ngd; vd;W 
cWjpaspf;fpNwd;. vd; cly; eyk; ghjpf;fg;gl;lhNyh> my;yJ 
vjpHghuhj> tof;fj;jpw;F khwhd Neha;Fwp njd;gl;lhNyh clNd 
,ij kUj;Jt mzpaplk; njhptpg;Ngd; vd cWjp mspf;Nwd;. 
 
 
gq;Nfw;gthpd; ifnahg;gk; / .................................................... ,lk; ........................................... 
fl;iltpuy; Nuif 
gq;Nfw;gthpd; ngaH kw;Wk; tpyhrk; ........................................................................................ 
Ma;thshpd; ifnahg;gk; /...................................................... ,lk; ............................................ 
Ma;thshpd; ngaH ......................................................................................................................... 
ikak; ...............................................................................................................................................  
fy;tpawpT ,y;yhjtw;F (ifNuif itj;jtHfSf;F) ,J mtrpak; Njit 
rhl;rpapd; ifnahg;gk; /...................................................... ,lk; ................................................ 
ngaH kw;Wk; tpyhrk; ................. ................................................................................................... 
5 MIN 15MIN 30MIN 5MIN 15MIN 30MIN 5MIN 15MIN 30MIN
1 19 M 50 158 1 60m 5min 6min t4 155m 4min 500m 240M 73 70 75 118 112 118 68 66 68 100 NIL
2 20 M 50 160 1 70m 5min 6min t6 135m 4min 490m 230M 74 68 74 112 108 104 68 66 66 100 NIL
3 22 F 35 150 1 75m 5min 5min t4 158m 5min 520m 260M 74 66 74 110 110 108 66 74 70 100 NIL
4 25 F 40 145 2 60m 5min 5min t4 150m 4min 540m 260M 74 68 74 114 112 116 68 68 74 100 NIL
5 30 F 45 150 1 90m 5min 5min t4 145m 4min 500m 250M 74 74 74 118 100 110 70 68 70 100 S
6 34 M 60 160 1 70m 5min 6min t6 135m 5min 450m 230M 74 88 74 116 118 116 72 74 70 100 NIL
7 32 M 65 165 2 60m 5min 6min t6 140m 5min 450m 240M 74 88 74 110 120 120 70 76 74 100 NIL
8 25 M 60 158 2 75m 5min 6min t5 150m 5mins 500m 260M 74 74 74 116 112 118 66 66 68 100 NIL
9 21 F 40 150 2 70m 4min 5min t4 150m 4min 530m 280M 74 76 74 118 116 116 68 72 70 100 NIL
10 40 F 50 148 2 80m 5min 5min t4 150m 4min 540m 250M 74 86 74 120 118 118 70 74 72 100 NIL
11 45 M 60 163 1 75m 5min 6min t6 140m 5min 450m 250M 74 88 74 118 92 120 72 76 74 100 NIL
12 22 F 35 150 1 90m 4min 5min t4 155m 4min 510m 230M 74 74 74 110 110 112 74 70 72 100 NIL
13 25 F 40 155 2 60m 5min 5min t4 150m 4min 500m 20M 74 64 74 124 95 116 66 64 68 100 NIL
14 26 M 70 168 2 85m 5min 6min t6 145m 4min 450m 230M 74 66 74 122 108 114 68 62 66 100 NIL
15 32 M 60 163 1 70m 5min 6min t6 145m 4min 430m 240M 74 61 74 130 134 132 62 58 62 100 NIL
16 28 M 55 165 1 75m 5min 6min t6 135m 5min 450m 240M 74 94 88 112 92 119 70 65 70 100 NIL
17 30 M 58 160 1 80m 5min 6min t6 145m 5min 530m 230M 74 74 70 118 112 118 68 66 68 100 NIL
18 42 F 55 155 2 90m 4min 6min t4 150m 4min 480m 260M 74 74 80 112 110 118 64 68 66 100 NIL
19 50 F 53 158 2 60m 4min 6min t4 155m 4min 500m 270M 74 74 74 112 95 114 76 66 70 100 NIL
20 29 M 60 163 2 75m 5min 6min t7 130m 5min 400m 250M 74 74 80 108 108 110 72 66 68 100 NIL
21 21 M 68 168 1 75m 5min 6min t6 140m 5min 450m 230M 74 74 76 110 108 112 66 66 68 100 S
22 22 F 38 145 2 60m 5min 5min t4 150m 4min 500m 220M 72 74 76 112 90 114 70 72 74 100 NIL
23 27 F 42 150 2 70m 4min 5min t4 140m 4min 450m 230M 80 84 82 110 110 118 72 74 76 100 NIL
24 28 F 48 155 1 75m 4min 5min t4 145m 4min 480m 230M 76 66 74 114 95 106 70 68 68 100 S
25 20 f 50 158 1 80m 5min 6min t4 150m 5min 500m 240M 72 64 72 112 108 104 68 66 64 100 NIL
26 25 m 60 162 2 60m 5min 6min t5 145m 5min 450m 220M 70 84 76 110 98 100 66 62 60 100 NIL
27 35 m 65 165 2 70m 5min 6min t5 145m 5min 500m 210M 76 82 78 108 98 95 64 58 56 100 NIL
28 28 f 50 156 1 75m 4min 5min t4 150m 4min 500m 210M 76 60 68 120 108 110 68 64 68 100 S
29 45 m 70 168 1 80m 5min 6min t6 135m 5min 430m 220M 72 66 66 120 95 114 68 62 66 100 NIL
30 50 m 65 165 2 60m 5min 6min t6 140m 5min 450m 220M 72 66 74 118 112 114 64 66 80 100 NIL
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5MIN 15MIN 30MIN 5MIN 15MIN 30MIN 5MIN 15MIN 30MIN
1 23 m 60 160 1 60m 7m 10m T6 140m 7m 280m 170m 60 80 68 90 98 95 70 64 56 100 NIL
2 25 m 65 165 1 70m 7m 10m T6 145m 7m 280m 180m 66 68 68 95 108 110 68 62 68 100 S
3 33 f 45 150 1 90m 6.5m 9m T5 138m 6m 320m 200m 72 58 78 118 108 114 70 66 66 100 S
4 35 m 40 163 2 90m 7m 10m T6 143m 7m 280m 150m 64 76 76 112 112 114 68 62 80 100 NIL
5 21 f 50 155 1 60m 6m 9m T5 135m 6m 280m 150m 78 70 78 108 88 108 78 78 68 100 NIL
6 50 f 55 153 2 90m 6m 9m T5 135m 6m 280m 160m 76 74 76 92 116 122 76 76 74 100 NIL
7 33 m 60 165 1 75m 7m 10m T6 135m 7m 250m 160m 74 72 74 114 114 120 74 74 72 100 S
8 42 f 55 158 1 90m 7m 9m T6 130m 6m 250m 160m 72 70 74 92 112 118 72 72 70 100 NIL
9 38 f 40 158 2 70m 7m 9m T6 132m 7m 280m 170m 70 64 70 110 110 116 74 74 74 100 NIL
10 33 f 45 145 2 60m 6m 8m T4 130m 6m 350m 200m 66 68 68 110 112 118 66 70 76 100 NIL
11 22 m 55 160 1 60m 7m 9m T6 140m 7m 280m 170m 68 70 78 95 118 114 64 72 66 100 S
12 45 m 60 165 2 90m 7m 10m T6 145m 7m 280m 160m 70 70 74 112 108 116 70 72 70 100 NIL
13 40 f 50 150 2 90m 7m 8m T5 135m 6m 300m 170m 68 74 68 108 114 118 74 64 70 100 NIL
14 25 f 40 155 1 65m 6m 9m T5 135m 6m 300m 170m 74 72 76 95 106 112 68 74 68 100 NIL
15 23 f 45 158 1 60m 7m 9m T6 135m 6m 250m 140m 68 68 76 104 112 116 68 70 70 100 NIL
16 36 f 50 160 1 70m 6m 9m T6 140m 6m 280m 170m 76 66 76 95 118 118 64 72 64 100 NIL
17 38 f 55 158 2 70m 7m 8m T6 138m 6m 280m 170m 68 62 70 108 116 118 68 66 70 100 S
18 33 m 60 170 2 75m 7m 10m T8 135m 7m 250m 160m 72 64 74 116 110 112 66 70 68 100 NIL
19 21 m 50 162 1 60m 7m 10m T7 132m 7m 250m 160m 66 62 78 108 100 112 60 68 72 100 NIL
20 25 m 65 167 1 75m 7m 10m T7 130m 7m 250m 150m 64 76 72 92 114 112 60 66 66 100 NIL
21 52 f 55 152 2 90m 7m 9m T5 137m 6m 300m 170m 76 66 70 90 112 110 66 70 68 100 S
22 55 f 50 158 1 90m 6m 9m T6 135m 6m 280m 170m 62 64 74 102 118 114 66 70 66 100 NIL
23 26 f 45 155 1 60m 7m 9m T5 135m 6m 300m 170m 64 68 76 90 112 114 68 74 72 100 NIL
24 28 m 60 163 1 75m 7m 9m T6 130m 7m 280m 150m 66 70 66 124 118 116 70 62 70 100 S
25 30 m 60 164 1 80m 7.5m 10m T6 130m 7.5m 280m 150m 64 64 72 94 102 110 68 68 70 100 NIL
26 37 f 55 152 2 80m 7m 9m T5 135m 6.5m 300m 170m 60 68 56 110 110 112 70 76 66 100 NIL
27 27 f 50 155 1 60m 7m 9m T5 135m 6.5m 300m 170m 72 62 70 120 120 112 60 66 66 100 NIL
28 45 m 55 165 2 90m 7m 9.5m T7 140m 7m 250m 150m 68 68 70 100 108 106 68 64 68 100 NIL
29 43 m 60 168 2 90m 8m 10m T7 145m 7.5m 250m 150m 70 62 74 104 104 108 62 60 66 100 NIL
30 40 f 50 158 2 90m 6.5m 9m T5 135m 6m 300m 170m 72 70 72 108 106 110 64 66 70 100 NIL
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